Kathmandu School of Law Review

P-ISSN : 2091-2110, E-ISSN : 2773-8159, DOI : 10.46985, Publisher : Kathmandu School of Law, Nepal
Annual flagship journal of Kathmandu School of Law, Nepal

Volume 8, Issue 1, April 2020
Articles

Compulsory Licensing: An Antidote for the Dissemination of Potential COVID-19 Cure?

PDF
  • Nandini Rajesh
    ,
  • Arya Kuttan
Nandini Rajesh
Final Year B.A. LL.B. (Hons) Student, School of Law, Christ (Deemed to be University)
Arya Kuttan
Final Year B.A. LL.B. (Hons) Student, School of Law, Christ (Deemed to be University)
DOI: https://doi.org/10.46985/kslr.v8i1.2131

Published 2021-07-09

How to Cite

Rajesh, N. . ., & Kuttan, A. . (2021). Compulsory Licensing: An Antidote for the Dissemination of Potential COVID-19 Cure?. Kathmandu School of Law Review, 8(1), 99–118. https://doi.org/10.46985/kslr.v8i1.2131
Crossref
Scopus
Google Scholar
Europe PMC

Abstract

This paper extensively examines the role of Compulsory Licensing in the Intellectual Property regime with regard to potential COVID-19 vaccinations. In Parts I and II, the paper analyzes the concept of compulsory licensing along with its need. Part III discusses the usage of the flexibilities laid down by the TRIPS Agreement by developing nations after the adoption of the Doha Declaration. This throws light on the status quo pertaining to its implications and repercussions and further helps in determining the situation upon invoking compulsory licensing in the current pandemic scenario. Parts IV and V discusses the pre-emptive measures taken by nations by means of laying forth foundational steps and the legal procedures involved in legitimizing the issuance of these licenses for potential COVID-19 vaccines. It discusses steps taken by various nations across the world, the reasons for doing so and their current legal status pertaining to the licenses. Part VI discusses in detail the diverging views that exist primarily between the United States of America and European Union. It entails discussions regarding accessibility and affordability of potential COVID-19 vaccines in the wake of a jurisprudential analysis of the existing legal provisions relating to compulsory licenses in both provinces. Further, Part VII lays down the negative implications which may arise while invoking compulsory licenses for potential COVID- 19 vaccines. This gives a detailed view of the need for the public healthcare to undertake a balanced approach of the interests of both, the patentee and the public at large. It also lays down the importance of adequate remuneration for the pharmaceutical companies which is often overlooked. Finally, Part VIII analyses both perspectives and lays down the importance of compulsory licensing with regard to both, accessibility and affordability.

PDF

Downloads

Download data is not yet available.

References

  1. Nina M. Hart, ‘COVID-19: International Trade and Access to Pharmaceutical Products’, Congressional Research Service, 2020, p. 1, available at https://crsreports.congress.gov/product/pdf/LSB/LSB10436, accessed on 15 June 2020.
  2. Christopher Garrison, ‘Intellectual Property Rights and Vaccines in Developing Countries’, World Health Organization, 2004, p.4, available at https://www.who.int/intellectualproperty/events/en/Background_ paper.pdf, accessed on 15 June 2020.
  3. World Health Organisation, ‘The Doha Declaration on the TRIPS agreement and Public Health’, available at https://www.who.int/medicines/areas/policy/doha_declaration/en/, accessed on 15 June 2020.
  4. Ibid.
  5. World Trade Organisation, ‘The separate Doha Declaration explained’, available at https://www.wto.org/english/tratop_e/trips_e/healthdeclexpln_e.htm, accessed 16 June 2020.
  6. Ibid.
  7. Ibid.
  8. Ibid.
  9. World Trade Organisation, ‘TRIPS and public health’, available at https://www.wto.org/english/ tratop_e/trips_e/pharmpatent_e.htm, accessed 18 June 2020.
  10. Trade-Related Aspects of Intellectual Property Rights Agreement, 1 January 1995, 1869 UNTS 299, Marrakesh, 15 April 1994, art. 30.
  11. Ibid, art. 31.
  12. Hart (n 1), p. 3.
  13. Cecilia Oh, ‘Compulsory licenses: recent experiences in developing countries’, Research Gate p.22, volume 1, 2006, p. 24, available at https://www.researchgate.net/publication/247835566_Compulsory_licenses_Recent_experiences_in_developing_countries, accessed on 20 June 2020.
  14. Ibid.
  15. Declaration of Period of Emergency (HIV/AIDS) Notice 2002 General Notice of Ministry of Justice, Legal and Parliamentary Affairs, Zimbabwe, notice 240
  16. Oh (n 13), p. 24.
  17. Letter of authorisation signed by the Minister of Justice, Legal and Parliamentary Affairs 2003, Ministry of Justice, Legal and Parliamentary Affairs, Zimbabwe
  18. Oh (n 13), p. 27.
  19. Ibid, p. 28.
  20. Ibid.
  21. James Packard Love, ‘Recent examples of the use of compulsory licenses on patents’, Knowledge Ecology International, 2007, p. 7, available at https://www.keionline.org/book/kei-rn-2007-2-recent-examples-of-compulsory-licensing-of-patents, accessed on 20 June 2020.
  22. Raadhika Gupta, ‘Compulsory licensing under TRIPS: How Far it Addresses Public Health Concerns in Developing Nations’, Journal Of Intellectual Rights p. 357, volume 15, 2010, p. 361, available at http://docs.manupatra.in/newsline/articles/Upload/6A48CA82-9412-43DE-8964-1CAC00062503.pdf, accessed on 27 June 2020.
  23. Ruth Gana, ‘Prospects for developing countries under the TRIPS Agreement’, VJTL p. 735, volume 29, 1996, p. 735.
  24. Samantha Silver & Lindsay Maclean, ‘COVID-19: vaccine development and compulsory licensing’, Kennedys, 2020, available at https://www.kennedyslaw.com/thought-leadership/article/covid-19-vaccinedevelopmentand-compulsory-licensing, accessed on 30 June 2020.
  25. Ibid.
  26. Ibid.
  27. Lucas Volman, The TRIPS Article 31 Tug of War: Developing Country Compulsory Licensing of Pharmaceutical Patents and Developed Country Retaliation, LL.M. Intellectual Property and Information Technology Law Thesis, University of Dublin, 2018, p. 19.
  28. Ibid.
  29. Anuradha Mukherjee, Ashwin Sapra, Pallavi Rao, Biplab Lenin & Shivanshu Bhardwaj, ‘To Protect or Not to Protect that is the Question: Patent Licensing in times of Covid-19 Pandemic’, India Corporate Law, 2020, available at https://corporate.cyrilamarchandblogs.com/2020/05/patent-licensing-in-times-of-covid-19pandemic/, accessed on 6 July 2020.
  30. Grace Ren, ‘ WHO, Costa Rica & Chile Announce Official Launch Of COVID-19 Intellectual Property Pool’, Health Policy Watch, 2020, available at https://healthpolicy-watch.news/who-costa-rica-announce-official-launch-of-covid-19-intellectual-property-pool, accessed on 10 July 2020.
  31. Luis Gil Abinader, ‘Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus’, keionline.org, 2020, available at https://www.keionline.org/32385, accessed on 10 July 2020.
  32. Ed Silverman, ‘Chilean lawmakers support compulsory licensing for coronavirus medicines and vaccines’, STAT Pharmalot, 2020, available at https://www.statnews.com/pharmalot/2020/03/18/chile-compulsory-licensing-coronavirus-covid19-vaccines/, accessed on 16 July 2020.
  33. Amy Sandys, ‘Forced cure: compulsory licensing in the coronavirus era’, juve-patent.com, 2020, available at https://www.juve-patent.com/news-and-stories/legal-commentary/forced-cure-compulsory-licensinginthe-coronavirus-era/, accessed on 18 July 2020.
  34. Steven Cattoor & Ine Letten, ‘Legislative initiatives on compulsory licensing in light of Covid-19’, exgo.be/ en, 2020, available at https://www.lexgo.be/en/papers/ip-it-telecom/intellectual-property-law/legislative-initiatives-on-compulsory-licensing-in-light-of-covid-19,136382.html, accessed on 21 July 2020.
  35. Nirmalya Syam, ‘Countries Are Adapting Intellectual Property Laws to Prioritise Health During COVID-19’, thewire.in, 2020, available at https://thewire.in/trade/intellectual-property-laws-covid-19, accessed on 22 July 2020.
  36. Cattoor &Letten (n 34).
  37. Hilary Wong, ‘The case for compulsory licensing during COVID-19’, Journal of Global health, volume 10:1, 2020, available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242884/, accessed on 24 July 2020.
  38. Okan Çan, ‘Turkey: Compulsory or Not? Licensing during the Covid-19 Pandemic’, mondaq.com,2020, https://www.mondaq.com/turkey/patent/940300/compulsory-or-not-licensing-during-the-covid-19pandemic, accessed on 27 July 2020.
  39. Andrew Green, ‘COVID-19: Countries race to strengthen compulsory licensing legislation’, Devex, 2020, available at https://www.devex.com/news/covid-19-countries-race-to-strengthen-compulsory-licensinglegislation97595, accessed on 27 July 2020.
  40. Okan Çan (n 38).
  41. Department of Finance, ‘The COVID-19 Emergency Response Act Receives Royal Assent’, www.canada.
  42. ca, 2020, available at https://www.canada.ca/en/department-finance/news/2020/03/the-covid-19-emergency-response-act-receives-royal-assent0.html, accessed on 29 July 2020.
  43. Ibid.
  44. Ibid.
  45. Hilary Wong (n 37).
  46. Nathaniel Lipkus, Simon Hodgett & Jaymie Maddox, ‘Government COVID-19 response includes compulsory licenses for patented emergency medical needs’, osler.com, 2020, available at https://www.osler.com/en/resources/regulations/2020/government-covid-19-response-includes-compulsory-licenses-for-patented-emergency-medical-needs, accessed on 29 July 2020.
  47. Stephen I. Selznick & Any Obando, ‘COVID-19 Impact: Changes to the Canadian Compulsory Licensing Scheme’, Cassels Insight, 2020, available at https://cassels.com/insights/covid-19-impact-changes-to-thecanadiancompulsive-licensing-scheme/, accessed on 29 July 2020.
  48. Luis Gil Abinader, ‘Legislative Committee in Ecuador approves resolution on compulsory licensing of patents relating to the coronavirus’, keionline.org, 2020, available at https://www.keionline.org/32429, accessed on 29 July 2020.
  49. Ibid.
  50. UNAIDS, ‘World leaders unite in call for a people’s vaccine against COVID-19’, UNAIDS, 2020, available at https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2020/ may/20200514_covid19-vaccine, accessed on 30 July 2020.
  51. Ibid.
  52. Adam Houldsworth, ‘Global calls for compulsory covid-19 patent licensing build’, iam-media.com, 2020, available at https://www.iam-media.com/coronavirus/global-calls-compulsory-covid-19-patent-licensingbuild, accessed on 30 July 2020.
  53. Ibid.
  54. Nirmalya Syam (n 35).
  55. Jerome H. Reichman, ‘Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options’, Journal of Law, Medicine & Ethics p. 247, volume 37:2, 2009, p. 252.
  56. Ibid, p. 252.
  57. Paris Convention for the Protection of Industrial Property, 7 July 1884, 828 UNTS 305, Paris, 20 March 1883.
  58. Nafsika Karavida, Dara Onofrio &Deena Merlen, ‘Patent Rights and Wrongs in the COVID-19 Pandemic: EU and U.S. Approaches to Compulsory Licensing’, IP Watchdog, 2020, available at https://www.
  59. ipwatchdog.com/2020/05/19/patent-rights-wrongs-covid-19-pandemic-eu-u-s-approaches-compulsorylicensing/id=121709/, accessed on 30 July 2020.
  60. Ibid.
  61. Robert T. Jones, ‘Fundamentals of International Licensing Agreements and Their Application in the European Community’, International Lawyer p.78, volume 7, 1973, p. 80, available at https://scholar.smu.edu/cgi/viewcontent.cgi?article=3918&context=til, accessed on 31 July 2020.
  62. Ibid, p. 82.
  63. Arthur H. Seidel, What the General Practitioner Should Know about Patent Law and Practice, Joint Committee on Continuing Legal Education of the American Law Institute collaborating with the American Bar Association , US, 4th edition, 1984, p. 97.
  64. Donna M. Gitter, ‘International Conflicts Over Patenting Human DNA Sequences in the United States and the European Union: An Argument for Compulsory Licensing and a Fair-Use Exception’, New York University Law Review, p. 1623, volume 76, 2001, p. 1681, available at https://www.nyulawreview.org/wpcontent/uploads/2018/08/NYULawReview-76-6-Gitter.pdf, accessed on 31 July 2020.
  65. Catherine S Corry, Compulsory Licensing of Patents- A Legislative History :Study of the Sub-Committee on Patents, Trademarks and Copyrights of the Senate Committee on the Judiciary, 85th Congress, 2D Session, Washington D.C. 10, United States Government Printing Office, United States, 1958.
  66. Continental Paper Bag Co. v Eastern Paper Bag Co., Supreme Court of United States, 1908, 210 U.S., p. 405.
  67. Ibid, p. 424.
  68. Senate Committee on the Judiciary (n 63).
  69. David J. Henry, ‘Multi-National Practice in Determining Provisions in Compulsory Patent Licensing’, J. Int’l L. & Econ p. 325, volume 11, 1976, p. 329.
  70. Constitution of the United States, 1788, art I, s 8, cl 8.
  71. B. R. Pravel, ‘Say No to More Compulsory Licensing Statutes’, Asia- Pacific Lawyers Association, volume 2:3, 1974, p.185.
  72. Ibid, p. 189.
  73. T. Arnold & P. Janicke, ‘Compulsory Licensing Anyone?’,J. PAT. OFF. SOc'Y, volume 55, 1973, p. 165.
  74. Leroy Whitaker, ‘Compulsory Licensing-Another Nail in the Coffin’, PAT. L.A.Q.J. p.155, volume 2, 1974, p.168.
  75. Application of Bayer (C.C.P.A. 1978) 568 F.2d 1357.
  76. Pravel (n 69).
  77. Cole M. Fauver, ‘Compulsory Patent Licensing in the United States: An Idea Whose Time Has Come’, Nw.
  78. J. Int'l L. & Bus p.666, volume 8, 1988, p .681.
  79. Michael Liu, William B. Feldman, Jerry Avorn &nAaron S. Kesselheim, ‘March-In Rights and Compulsory Licensing- Safety Nets for Access to a COVID-19 Vaccine’, Health Affairs Blog, 2020, available at https://www.healthaffairs.org/do/10.1377/hblog20200501.798711/full/, accessed on 31 July 2020.
  80. William Alan Reinsch, Jack Caporal & Sanvid Tuljapurkar, ‘Compulsory Licensing: A Cure for Distributing the Cure?’, Center for Strategic & International Studies, 2020, available at https://www.csis.org/analysis/compulsory-licensing-cure-distributing-cure, accessed on 2 August 2020.
  81. Christopher Wadlow, Enforcement of Intellectual Property in European and International Law, Sweet & Maxwell, 1st edition, 1998, p. 257.
  82. Christopher J. Meyers, ‘European Union Competition Law and Intellectual Property Licensing: TransAtlantic Convergence and Compulsory Licensing’, AIIPL p. 135, volume 11, 2005, pp. 149-150.
  83. Christopher Bellamy & Graham D. Child, ‘European Union Law of Competition’, in Peter Roth QC & Vivien Rose (eds), Oxford University Press, 2008, p. 26.
  84. Ibid, p. 1047.
  85. Meyers (n. 79), pp. 143-144.
  86. Ibid.
  87. Rita Coco, ‘Antitrust Liability for Refusal to License Intellectual Property: A Comparative Analysis and the International Setting’, Marq. Intell. Prop. L. Rev, volume 12, 2008, p. 10.
  88. Melanie J. Reichenberger, ‘The Role of Compulsory Licensing in Unilateral Refusals to Deal: Have the United States and European Approaches Grown Further Apart After IMS?’, J. Corp. L p. 563, volume 31, 2006, pp. 563-564.
  89. Reichenberger (n 85), pp. 564-565.
  90. Susan K. Sell, ‘The Quest for Global Governance in Intellectual Property and Public Health: Structural, Discursive, and Institutional Dimensions’, Temp. L. Rev. p. 363, volume 77, 2004, pp. 385-386, available at https://www.researchgate.net/publication/239928829_The_Quest_for_Global_Governance_in_ Intellectual_Property_and_Public_Health_Structural_Discursive_and_Institutional_Dimensions, accessed on 2 August 2020.
  91. World Intellectual Property Organization, ‘Member States’, available on https://www.wipo.int/members/ en/, accessed on 2 August 2020.
  92. Karavida, Onofrio & Merlen (n 57).
  93. World Trade Organisation, ‘Decision removes final patent obstacle to cheap drug imports’, available at https://www.wto.org/english/news_e/pres03_e/pr350_e.htm, accessed on 2 August 2020.
  94. Padmanabha Ramanujam & Yugank Goya, ‘One View of Compulsory Licensing: Comparative Perspectives from India and Canada’, Marq. Intellectual Property L. Rev p. 369, volume 18, 2014, p. 400.
  95. Ibid.
  96. R. C. Bird, ‘Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines while Minimizing Investment Side Effects’, JLME p. 209, volume 37, 2009, p. 211.
  97. Ibid, p. 212.
  98. Gupta (n 22), p. 359.
  99. Ibid.
  100. Fauver (n 75), p. 668.
  101. David E. Bloom & David Canning, ‘The Health and Wealth of Nations’, Science p. 1207, volume 287:5456, 2000, p. 1209, available at https://science.sciencemag.org/content/287/5456/1207.summary, accessed on 3 August 2020.
  102. Frederick M. Abbott, ‘IP and Public Health: Meeting the Challenge of Sustainability’, Working Paper No. 7/2011, Global Health Programme, Geneva, Switzerland, 2011, p. 32, available at http://ssrn.com/ abstract=1965458, accessed on 3 August 2020.